Scientists at the University of Pennsylvania’s Perelman School of Medicine have identified the cell surface receptor protein TIE2 as a drug target that could prevent the formation of abnormal blood vessels responsible for brain hemorrhages, strokes, and seizures. The finding, published in the Journal of Experimental Medicine, centers on a small, orally available drug called rebastinib that blocked the development of dangerous vascular lesions in mouse models. What makes TIE2 especially compelling is that separate research teams working on different types of brain bleeds have independently converged on the same signaling pathway, suggesting a shared biological vulnerability that cuts across conditions.
How TIE2 Signaling Keeps Brain Vessels Intact
TIE2 is a receptor found on the surface of endothelial cells, the thin layer of cells lining every blood vessel in the body. When TIE2 is properly activated, it helps maintain tight junctions between endothelial cells, preventing blood from leaking into surrounding tissue. The brain is especially sensitive to this process because its blood-brain barrier depends on those junctions to keep plasma proteins and immune cells out of neural tissue.
A protein called angiopoietin-2 (ANG2 or ANGPT2) acts as a natural antagonist of TIE2. When ANG2 levels rise, TIE2 signaling weakens, endothelial junctions loosen, and vessels become fragile. This mechanism has been documented across several distinct brain conditions. In mouse models of hereditary hemorrhagic telangiectasia (HHT), researchers found that ANG2 upregulation and impaired TIE2 activity were shared features that drove the formation of brain arteriovenous malformations, or AVMs. These AVMs are tangled, weak-walled vessels that can rupture and cause life-threatening hemorrhage.
Rebastinib Blocks Lesion Formation in HHT Models
The Penn team, led by Kahn and colleagues, found that inhibiting TIE2 with rebastinib prevented the development of these vascular lesions. Rebastinib is a small, orally available drug, which matters because many experimental vascular therapies require intravenous delivery or complex dosing regimens. An oral pill that targets the same pathway responsible for AVM formation could eventually simplify treatment for patients with HHT, a genetic disorder that affects roughly one in 5,000 people worldwide and currently has no approved therapy to prevent brain AVMs from forming.
The logic behind TIE2 inhibition in HHT may seem counterintuitive at first. If TIE2 activation normally stabilizes vessels, why would blocking it help? The answer lies in the specific disease context: in HHT, loss of other signaling proteins (such as endoglin or ALK1) causes endothelial cells to become hyperresponsive to growth signals routed through TIE2, driving abnormal vessel proliferation rather than stability. Blocking that overactive signal with rebastinib appears to restore a more normal vascular architecture, at least in preclinical models.
Parallel Evidence in Preterm and Hypertensive Brain Bleeds
The Penn findings do not exist in isolation. A separate line of research on germinal matrix hemorrhage (GMH), the most common cause of brain bleeding in premature infants, has shown that ANGPT2 is elevated when TGF-beta/ALK5 signaling breaks down in pericytes, the support cells that wrap around small blood vessels. In that model, pharmacologic blockade of ANGPT2 during a defined embryonic window significantly reduced hemorrhage. The mechanism is essentially the mirror image of the HHT work: too much ANG2 destabilizes TIE2 signaling, and removing that excess restores vessel integrity.
In adult hypertensive intracerebral hemorrhage (ICH), the pattern recurs. A study in Experimental Neurology reported that TIE2 expression is reduced in cerebral vessels of hypertensive ICH mice. Modulating TIE2 affected brain endothelial cell behaviors including proliferation and survival, positioning TIE2 as a therapeutic target in a condition whose molecular underpinnings remain poorly understood. ICH is one of the deadliest forms of stroke, killing roughly 40 percent of patients within a month, and effective prevention strategies are largely limited to blood pressure control.
Additional work has begun to connect these vascular defects to genetic risk. In a recent investigation of stroke susceptibility, scientists showed that the transcription factor FOXF2 regulates cerebrovascular stability and that its disruption increases the likelihood of small-vessel disease. In that study, altered FOXF2 signaling influenced endothelial behavior in ways that intersect with angiopoietin–TIE2 pathways, hinting that inherited variation in these networks could help explain why some people are more vulnerable to hemorrhagic or ischemic events than others.
Beyond Hemorrhage: Barrier Repair and Stroke Recovery
TIE2’s relevance extends past hemorrhage prevention into broader vascular repair. Research on glioblastoma, the most aggressive brain cancer, demonstrated that direct TIE2 activation with an agonistic antibody restored vascular barrier properties in tumor-associated brain vessels, reducing leakage and improving endothelial junction integrity markers. While that study was not a brain bleed model, it confirmed that TIE2 activation can tighten the blood-brain barrier even under severe pathological stress.
Older foundational work on diabetic stroke established that reduced Ang1/TIE2 signaling correlates with blood-brain barrier leakage in ischemic stroke under diabetic conditions. Animals with lower Ang1 and TIE2 levels showed more extensive edema and worse neurological outcomes, supporting the idea that a robust TIE2 axis is protective not only against bleeding but also against secondary damage after vessel occlusion.
Newer preclinical studies in models of intracerebral hemorrhage are now testing whether pharmacologically boosting TIE2 can improve recovery once bleeding has already occurred. In one such experiment, investigators administered a small-molecule agent after ICH and found that enhancing endothelial stability reduced edema and neuronal loss. Although the compound in that work did not directly target TIE2, the downstream effects on barrier function and inflammation overlapped with those seen in TIE2-focused research, reinforcing the notion that stabilizing the neurovascular unit is a promising strategy for both acute and chronic phases of brain injury.
A Converging Therapeutic Strategy
Taken together, these studies sketch a coherent picture. In HHT, overactive TIE2 signaling in a genetically sensitized background drives malformed vessels that can be curtailed by rebastinib. In premature infants, excess ANG2 undermines TIE2 and predisposes fragile germinal matrix vessels to rupture, a problem that can be mitigated by blocking ANG2. In hypertensive adults, TIE2 appears pathologically suppressed in small arteries deep within the brain, and restoring its function could shore up those vessels before or after they bleed. Across ischemic stroke, glioblastoma, and diabetic vascular disease, the same axis repeatedly emerges as a key regulator of blood-brain barrier integrity.
This convergence does not mean a single drug will work for every patient with a brain bleed. The direction of intervention—whether to inhibit TIE2, activate it, or modulate its ligands—depends on the underlying biology of each disease. Timing will also be critical: therapies that prevent lesion formation in a developmental window may not help once a hemorrhage is underway, and agents that tighten the barrier too aggressively could, in theory, impair immune surveillance or tissue repair.
Still, the identification of TIE2 as a shared node across such diverse conditions offers a rare opportunity. It provides a mechanistic framework for unifying disorders that have long been treated as separate entities and suggests concrete molecular endpoints—such as ANG2 levels, TIE2 phosphorylation, and junctional protein expression—that future clinical trials can measure. With an orally available candidate like rebastinib already showing efficacy in animal models, and complementary approaches that boost or fine-tune TIE2 signaling in other contexts, the field is moving toward targeted vascular therapies that could prevent some of the most devastating forms of brain injury.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
